Mechanistic Target of Rapamycin Complex 1 Expands Th17 and IL-4+ CD4-CD8-Double-Negative T Cells and Contracts Regulatory T Cells in Systemic Lupus Erythematosus

被引:130
作者
Kato, Hiroshi
Perl, Andras
机构
[1] SUNY Upstate Med Univ, Coll Med, Dept Med, Div Rheumatol, Syracuse, NY 13210 USA
[2] SUNY Upstate Med Univ, Coll Med, Dept Microbiol & Immunol, Div Rheumatol, Syracuse, NY 13210 USA
[3] SUNY Upstate Med Univ, Coll Med, Dept Biochem & Mol Biol, Div Rheumatol, Syracuse, NY 13210 USA
基金
美国国家卫生研究院;
关键词
ROR-GAMMA-T; MAMMALIAN TARGET; DISEASE-ACTIVITY; DECREASED PRODUCTION; INTERFERON-GAMMA; HELPER-CELLS; MTOR KINASE; TGF-BETA; IN-VIVO; DIFFERENTIATION;
D O I
10.4049/jimmunol.1301859
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mechanistic target of rapamycin (mTOR) is activated in CD4-CD8-double-negative (DN) T cells and its blockade is therapeutic in systemic lupus erythematosus (SLE) patients. Murine studies showed the involvement of mTOR complex 1 (mTORC1) and 2 (mTORC2) in the differentiation of Th1/Th17 cells and Th2 cells, respectively. In this study, we investigated the roles of mTORC1 and mTORC2 in T cell lineage development in SLE and matched healthy control (HC) subjects. mTORC1 activity was increased, whereas mTORC2 was reduced, as assessed by phosphorylation of their substrates phosphorylated S6 kinase 1 or phosphorylated S6 ribosomal protein and phosphorylated Akt, respectively. Rapamycin inhibited mTORC1 and enhanced mTORC2. IL-4 expression was increased in freshly isolated CD8(+) lupus T cells (SLE: 8.09 +/- 1.93%, HC: 3.61 +/- 0.49%; p = 0.01). DN T cells had greater IL-4 expression than CD4(+) or CD8(+) T cells of SLE patients after 3-d in vitro stimulation, which was suppressed by rapamycin (control: 9.26 +/- 1.48%, rapamycin: 5.03 +/- 0.66%; p < 0.001). GATA-3 expression was increased in CD8(+) lupus T cells (p < 0.01) and was insensitive to rapamycin treatment. IFN-gamma expression was reduced in all lupus T cell subsets (p = 1.0 x 10(-5)) and also resisted rapamycin. IL-17 expression was increased in CD4(+) lupus T cells (SLE: 3.62 +/- 0.66%, HC: 2.29 +/- 0.27%; p = 0.019), which was suppressed by rapamycin (control: 3.91 +/- 0.79%, rapamycin: 2.22 +/- 0.60%; p < 0.001). Frequency of regulatory T cells (Tregs) was reduced in SLE (SLE: 1.83 +/- 0.25%, HC: 2.97 +/- 0.27%; p = 0.0012). Rapamycin inhibited mTORC1 in Tregs and promoted their expansion. Neutralization of IL-17, but not IL-4, also expanded Tregs in SLE and HC subjects. These results indicate that mTORC1 expands IL-4(+) DN T and Th17 cells, and contracts Tregs in SLE. The Journal of Immunology, 2014, 192: 4134-4144.
引用
收藏
页码:4134 / 4144
页数:11
相关论文
共 77 条
[21]   RETRACTED: Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus (Retracted Article) [J].
Doreau, Agnes ;
Belot, Alexandre ;
Bastid, Jeremy ;
Riche, Benjamin ;
Trescol-Biemont, Marie-Claude ;
Ranchin, Bruno ;
Fabien, Nicole ;
Cochat, Pierre ;
Pouteil-Noble, Claire ;
Trolliet, Pierre ;
Durieu, Isabelle ;
Tebib, Jacques ;
Kassai, Berhouz ;
Ansieau, Stephane ;
Puisieux, Alain ;
Eliaou, Jean-Francois ;
Bonnefoy-Berard, Nathalie .
NATURE IMMUNOLOGY, 2009, 10 (07) :778-U142
[22]   SWITCH OF CD8 T-CELLS TO NONCYTOLYTIC CD8-CD4- CELLS THAT MAKE T(H)2 CYTOKINES AND HELP B-CELLS [J].
ERARD, F ;
WILD, MT ;
GARCIASANZ, JA ;
LEGROS, G .
SCIENCE, 1993, 260 (5115) :1802-1805
[23]   Rapamycin reduces disease activity and normalizes T-Cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. [J].
Fernandez, David ;
Bonilla, Eduardo ;
Mirza, Naureen ;
Niland, Brian ;
Perl, Andras .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :S261-S261
[24]   Activation of Mammalian Target of Rapamycin Controls the Loss of TCRζ in Lupus T Cells through HRES-1/Rab4-Regulated Lysosomal Degradation [J].
Fernandez, David R. ;
Telarico, Tiffany ;
Bonilla, Eduardo ;
Li, Qing ;
Banerjee, Sanjay ;
Middleton, Frank A. ;
Phillips, Paul E. ;
Crow, Mary K. ;
Oess, Stefanie ;
Muller-Esterl, Werner ;
Perl, Andras .
JOURNAL OF IMMUNOLOGY, 2009, 182 (04) :2063-2073
[25]   CD39+Foxp3+ Regulatory T Cells Suppress Pathogenic Th17 Cells and Are Impaired in Multiple Sclerosis [J].
Fletcher, Jean M. ;
Lonergan, Roisin ;
Costelloe, Lisa ;
Kinsella, Katie ;
Moran, Barry ;
O'Farrelly, Cliona ;
Tubridy, Niall ;
Mills, Kingston H. G. .
JOURNAL OF IMMUNOLOGY, 2009, 183 (11) :7602-7610
[26]   Fuel feeds function: Energy metabolism and the T-cell response [J].
Fox, CJ ;
Hammerman, PS ;
Thompson, CB .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (11) :844-852
[27]   The Percentage of FoxP3+Helios + Treg Cells Correlates Positively With Disease Activity in Systemic Lupus Erythematosus [J].
Golding, Amit ;
Hasni, Sarfaraz ;
Illei, Gabor ;
Shevach, Ethan M. .
ARTHRITIS AND RHEUMATISM, 2013, 65 (11) :2898-2906
[28]   Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages [J].
Harrington, LE ;
Hatton, RD ;
Mangan, PR ;
Turner, H ;
Murphy, TL ;
Murphy, KM ;
Weaver, CT .
NATURE IMMUNOLOGY, 2005, 6 (11) :1123-1132
[29]  
Horwitz DA, 1998, ARTHRITIS RHEUM, V41, P838, DOI 10.1002/1529-0131(199805)41:5<838::AID-ART10>3.0.CO
[30]  
2-S